Highlights Biora Therapeutics, Inc.

Equities

BIORQ

US74319F4046

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 11:32:51 06/11/2025 pm IST			5-day change	1st Jan Change
0.000100 ^USD	-.--%		-.--%	-

30/12	Biora Therapeutics, Inc. Went Out of Business	CI
27/25/27	Motion For Case Conversion Approved for Biora Therapeutics, Inc.	CI

Highlights

30/24/30	Biora Therapeutics Files for Chapter 11, Secures $10.25 Million Financing for Sale Process	MT
10/24/10	Top Midday Decliners	MT
10/24/10	Investors Look Ahead to Key Inflation Data as US Futures Tread Water in Tuesday's Premarket	MT
15/24/15	Biora Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	CI
14/24/14	Earnings Flash (BIOR) BIORA THERAPEUTICS Posts Q3 Revenue $32,000	MT
29/24/29	Biora Therapeutics Plans $3 Million Registered Direct Offering; Shares Fall	MT
11/24/11	Biora Therapeutics Board Approves 1-for-10 Reverse Stock Split	MT
28/24/28	Biora Therapeutics Gets Extension to Regain Compliance With Nasdaq Listing Requirements	MT
26/24/26	Biora Therapeutics Files Registration Statement on Behalf of Selling Stockholders	MT
15/24/15	Athyrium Capital Management Engages with Biora Therapeutics	CI
13/24/13	Biora Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	CI
13/24/13	Earnings Flash (BIOR) BIORA THERAPEUTICS Posts Q2 Revenue $318,000	MT
18/24/18	Biora Therapeutics, Inc. Announces Supplemental Data from Phase 1 Clinical Trial of BT-600 as Presented At KOL Event	CI
09/24/09	Athyrium Capital Management Engages in Discussions with Biora Therapeutics Inc	CI
01/24/01	Biora Therapeutics, Inc. Announces Positive Clinical Trial Results for BT-600	CI
16/24/16	Biora Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
16/24/16	Earnings Flash (BIOR) BIORA THERAPEUTICS Reports Q1 Revenue $542,000	MT
30/24/30	Biora Therapeutics, Inc. Announces Completion of Multiple-Ascending Dose Cohorts for Clinical Trial of BT-600	CI
04/24/04	Biora Therapeutics, Inc. Achieves Positive Interim Results for Clinical Trial of BT-600, Advancing NaviCap Platform Development	CI
27/24/27	Biora Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
27/24/27	Biora Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	CI
26/24/26	Biora Therapeutics, Inc. Announces Successful Completion of Single-Ascending Dose Cohorts of Phase 1 Clinical Study of BT-600	CI
08/24/08	Biora Therapeutics, Inc. Announces Initiation of Phase 1 Clinical Study of BT-600	CI
02/24/02	Biora Therapeutics, Inc. Progresses Research Collaboration for the BioJet Systemic Oral Delivery Platform with AstraZeneca	CI
21/23/21	Athyrium Capital Management Engages in Discussions with Biora Therapeutics	CI